BookR: School of Health Core Facilities Booking
PubMed Publications| Keyword search (4,163 papers available) |  |
"Aprikian S" Authored Publications:
| Title | Authors | PubMed ID | |
|---|---|---|---|
| 1 | Medical cannabis is effective for cancer-related pain: Quebec Cannabis Registry results | Aprikian S; Kasvis P; Vigano M; Hachem Y; Canac-Marquis M; Vigano A; | 37130724 PERFORM |
| 2 | Metabolic networks of the human gut microbiota. | Selber-Hnatiw S, Sultana T, Tse W, Abdollahi N, Abdullah S, Al Rahbani J, Alazar D, Alrumhein NJ, Aprikian S, Arshad R, Azuelos JD, Bernadotte D, Beswick N, Chazbey H, Church K, Ciubotaru E, D'Amato L, Del Corpo T, Deng J, Di Giulio BL, Diveeva D, Elahie E, Frank JGM, Furze E, Garner R, Gibbs V, Goldberg-Hall R, Goldman CJ, Goltsios FF, Gorjipour K, Grant T, Greco B, Guliyev N, Habrich A, Hyland H, Ibrahim N, Iozzo T, Jawaheer-Fenaoui A, Jaworski JJ, Jhajj MK, Jones J, Joyette R, Kaudeer S, Kelley S, Ki | 31799915 BIOLOGY |
| Title: | Medical cannabis is effective for cancer-related pain: Quebec Cannabis Registry results | ||||
| Authors: | Aprikian S, Kasvis P, Vigano M, Hachem Y, Canac-Marquis M, Vigano A | ||||
| Link: | https://pubmed.ncbi.nlm.nih.gov/37130724/ | ||||
| DOI: | 10.1136/spcare-2022-004003 | ||||
| Publication: | BMJ supportive & palliative care | ||||
| Keywords: | cancer; pain; supportive care; symptoms and symptom management; | ||||
| PMID: | 37130724 | Category: | Date Added: | 2023-05-03 | |
| Dept Affiliation: |
PERFORM
1 School of Medicine, Royal College of Surgeons, Dublin, Ireland. 2 Medical Cannabis Program in Oncology, Cedars Cancer Centre, McGill University Health Centre, Montreal, Quebec, Canada. 3 McGill Nutrition and Performance Laboratory, Montreal, Quebec, Canada. 4 Department of Health, Kinesiology and Applied Physiology, Concordia University, Montreal, Quebec, Canada. 5 Department of Science, McGill University, Montreal, Quebec, Canada. 6 Department of Internal Medicine, Harvard Medical School, Boston, Massachusetts, USA. 7 Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada. 8 Medical Cannabis Program in Oncology, Cedars Cancer Centre, McGill University Health Centre, Montreal, Quebec, Canada antonio.vigano@mcgill.ca. 9 Division of Supportive and Palliative Care, McGill University Health Centre, Montreal, Quebec, Canada. |
||||
Description: |
Objectives: To evaluate the safety and effectiveness of medical cannabis (MC) in reducing pain and concurrent medications in patients with cancer. Methods: This study analysed data collected from patients with cancer who were part of the Quebec Cannabis Registry. Brief Pain Inventory (BPI), revised Edmonton Symptom Assessment System (ESAS-r) questionnaires, total medication burden (TMB) and morphine equivalent daily dose (MEDD) recorded at 3-month, 6-month, 9-month and 12-month follow-ups were compared with baseline values. Adverse events were also documented at each follow-up visit. Results: This study included 358 patients with cancer. Thirteen out of 15 adverse events reported in 11 patients were not serious; 2 serious events (pneumonia and cardiovascular event) were considered unlikely related to MC. Statistically significant decreases were observed at 3-month, 6-month and 9-month follow-up for BPI worst pain (5.5±0.7 baseline, 3.6±0.7, 3.6±0.7, 3.6±0.8; p<0.01), average pain (4.1±0.6 baseline, 2.4±0.6, 2.3±0.6, 2.7±0.7; p<0.01), overall pain severity (3.7±0.5 baseline, 2.3±0.6, 2.3±0.6, 2.4±0.6; p<0.01) and pain interference (4.3±0.6 baseline, 2.4±0.6, 2.2±0.6, 2.4±0.7, p<0.01). ESAS-r pain scores decreased significantly at 3-month, 6-month and 9-month follow-up (3.7±0.6 baseline, 2.5±0.6, 2.2±0.6, 2.0±0.7, p<0.01). THC:CBD balanced strains were associated with better pain relief as compared with THC-dominant and CBD-dominant strains. Decreases in TMB were observed at all follow-ups. Decreases in MEDD were observed at the first three follow-ups. Conclusions: Real-world data from this large, prospective, multicentre registry indicate that MC is a safe and effective complementary treatment for pain relief in patients with cancer. Our findings should be confirmed through randomised placebo-controlled trials. |
